MoonLake Immunotherapeutics (MLTX) Q3 2025 performance reflects aggressive investment and significant operational setbacks. The company generated no revenue for the nine months ended September 30, 2025, with the Net Loss widening sharply to \((167.3) million (vs. \)(74.8)M prior year), leading to a diluted Loss Per Share of \((2.61). This deterioration is primarily driven by a 102.8% surge in Research and Development (R&D) spending, reaching \)146.9 million YTD.
Pipeline and Strategy: MLTX maintains a single focus on its lead candidate, Sonelokimab (SLK), for inflammatory diseases. Developmen
...